sorafenib has been researched along with dicumarol in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (dicumarol) | Trials (dicumarol) | Recent Studies (post-2010) (dicumarol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,260 | 33 | 110 |
| Protein | Taxonomy | sorafenib (IC50) | dicumarol (IC50) |
|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | 0.0026 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.3 | |
| NAD | Homo sapiens (human) | 0.2585 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 4.426 | |
| Proprotein convertase subtilisin/kexin type 7 | Homo sapiens (human) | 1.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Luo, J; Mu, X; Wang, Z; Yang, Q; Zhao, Y | 1 |
2 other study(ies) available for sorafenib and dicumarol
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha.
Topics: Antineoplastic Agents; Aspartic Acid; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cytochromes c; Dicumarol; Female; Glutathione; Humans; Hypoxia; Micelles; NAD; NADP; Nitroimidazoles; Oxygen; Phosphates; Polyethylene Glycols; Polymers; Quinones; Sorafenib; Thioredoxins | 2022 |